Skip to content


  • Meeting abstract
  • Open Access

The double-faced role of P2X7 receptors in toxin-induced animal models of Parkinson’s disease

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 2
BMC Pharmacology201111 (Suppl 2) :A56

  • Published:


  • PC12 Cell
  • Substantia Nigra
  • P2X7 Receptor
  • MPTP Treatment
  • Rotenone Treatment


Previous studies indicate a role of P2X7 receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X7 receptors influenced dopaminergic cell death in various models of Parkinson’s disease (PD).


PC12 cells and primary mesencephalic neurons were used in culture, and the striatum and the substantia nigra were prepared from wild-type and P2X7 receptor knockout mice. Rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatments were applied in vitro and in vivo to reproduce neurochemical hallmarks of PD. Receptor expression, cell survival indicators, and endogenous biogenic amine, amino acid, adenine nucleotide and endocannabinoid contents were analyzed.


mRNA encoding P2X7 and P2X4 receptors was up-regulated after treatment of PC12 cells with MPTP. P2X7 antagonists protected against MPTP- and rotenone-induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7 receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X4 receptors was higher in P2X7 knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7 receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7 knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7-deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-arachidonoyl glycerol (2-AG), was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7 receptors.


We conclude that P2X7 receptor deficiency or inhibition does not support the survival of dopaminergic neurons in in vivo or in vitro models of PD.

Authors’ Affiliations

Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary
Department of Gene Technology and Developmental Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary


© Sperlágh et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.